The funding is set to support the initiation various trials of its assets. Credit: SOMKID THONGDEE/Shutterstock.

Disc Medicine (Disc) has secured a $200m non-dilutive term loan facility from Hercules Capital to advance the clinical trials of assets across its portfolio.

Through the financing, the company also aims to further bolster its financial and operational flexibility.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The loan facility comprises up to four tranches, with a $30m tranche already drawn at closing and further funds available through H2 2026 at Disc’s option.

An additional $80m is available at Disc’s discretion, with another $65m contingent on attaining certain performance milestones.

The final tranche of $25m will be accessible during the interest-only period, subject to the consent of Hercules Capital.

The funding is set to support various activities, including the launch of a confirmatory study of bitopertin for erythropoietic protoporphyria (EPP), Phase II studies for DISC-0974 and DISC-3405 in anaemia of myelofibrosis (MF) and in polycythaemia vera (PV), respectively.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company also plans to commence a multiple dose trial in anaemia of non-dialysis dependent chronic kidney disease (NDD-CKD).

Disc Medicine chief financial officer Jean Franchi said:  “With this non-dilutive $200m financing, we are well-positioned as we prepare for upcoming catalysts across our entire pipeline including the potential initiation of a confirmatory trial of bitopertin in EPP by mid-2025 and related commercial preparations.

“Not only does this non-dilutive financing strengthen what we believe to be an already strong financial position, it provides optionality and strategic flexibility in future capital formation as we continue to advance our pipeline in pursuit of our mission to deliver innovative treatments to patients suffering from serious hematologic diseases.”

Recently, the company announced a US Food and Drug Administration (FDA) agreement on the regulatory path for bitopertin in treating the rare skin condition erythropoietic protoporphyria (EPP).